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Abstract
Topical instillation is the most widely preferred noninvasive route of drug 
administration to treat diseases affecting the anterior segment of the eye. 
Nonetheless, the ocular bioavailability for deeper ocular tissues is very low. 
Different routes of administration, such as intravitreal injections, periocular 
injections, and systemic administration, have been used to deliver drugs into the 
posterior segment ocular tissues. However, the presence of blood-retinal barriers 
(BRBs) makes systemic administration an impractical approach, whereas the drug 
delivery with the periocular administration route is compromised by ocular static 
and dynamic barriers. On the other hand, intravitreal injection, the most common 
and widely recommended route for drug administration to treat posterior ocular 
diseases, is related to several side effects such as endophthalmitis, hemorrhage, 
retinal detachment, and poor patient tolerance. Diverse strategies to overcome 
ocular barriers have been explored for topical drop formulations in order to deliver 
drugs into the posterior segment ocular tissues. In this chapter, we will review the 
promising topical nanocarriers for drug delivery into the posterior segment of the 
eye, emphasizing the use of liposomes for topical ophthalmic formulations target-
ing the vitreous cavity and the retina.
Keywords: liposomes, retina, vitreous, ocular posterior segment, nanocarriers,  
novel drug delivery system
1. Introduction and objective
The eyeball may be divided into two parts: the anterior and the posterior 
segments. The anterior segment consists of the pupil, cornea, iris, ciliary body, 
aqueous humor, and lens, whereas the posterior segment is comprised of the 
vitreous humor, macula, retina, choroid, and optic nerve. The retina is the sensitive 
layer which creates nerve impulses that are transmitted through the optic nerve to 
the brain. The macula is a specialized area of the retina that is responsible for the 
central, high-resolution color vision [1]. The retina and macula can suffer from 
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different disabling illnesses, such as age-related macular degeneration, cystoid 
macular edema, diabetic retinopathy, and ocular vascular occlusion, which are the 
leading causes of nonreversible vision impairment [2, 3]. These retinal disorders 
could be pharmacologically addressed; however, the efficient and safe delivery of 
drugs to the retinal tissue is not a completely solved subject.
Compared to drug delivery to other organs, ocular drug delivery faces significant 
challenges posed by various sophisticated ocular barriers. Many of these barriers 
are inherent and unique to ocular anatomy and physiology, making it a challenging 
task for drug delivery innovations. Corneal and conjunctival epithelium, blood-
aqueous barriers (BAB), and blood-retinal barriers (BRBs) are the fundamental 
structures that restrict the passage of molecules and fluids to the retina and impede 
drug penetration; moreover, various elimination mechanisms, such as tear turn-
over, nasolacrimal drainage, protein binding, systemic absorption, and enzymatic 
degradation, limit the ocular bioavailability of drugs [4, 5]. Conventional drug 
administration systems such as eye drops, suspensions, and ointments are optimal 
in the treatment of the ocular surface (corneal and conjunctiva tissues) and anterior 
segment disorders. Nevertheless, due to the ocular barriers, drugs barely get into the 
posterior ocular segment [1]. It is well known that ocular bioavailability after the 
topical administration of a drug is generally <5% [4, 5].
Therefore, intravitreal (IVT) injections, which circumvent the ocular barriers, 
are the most frequent pathway to deliver drugs for the treatment of posterior ocular 
globe disorders. Today, the use of IVT injections has become the most common 
intraocular procedure worldwide [6] and the standard drug delivery method for the 
treatment of retinal diseases [2, 3]. Intravitreal injections are now routinely used 
for the intraocular administration of drugs such as corticosteroids, antimetabolites, 
antibiotics, and anti-VEGF therapies [7–11].
Although IVT injections are a well-described and feasible route for releasing drugs 
into the posterior pole of the eye, this procedure is associated with severe complica-
tions such as endophthalmitis, lens injury, and retinal detachment [12–14]. Moreover, 
it might be a burden for physicians, the health system, and patients with poor compli-
ance in many cases [15]. Furthermore, the administration of IVT injections requires 
highly specialized human resources and special infrastructure, resulting in an 
expensive therapy option [16]. Research initiatives are continuously being proposed 
worldwide at fast pace by apex organizations and pharmaceutical companies in order 
to find a safer and more effective ocular drug delivery method for ocular use.
Nanostructured carriers or nanocarriers (nanomaterials) have proven to be an 
effective and slightly invasive drug delivery system to keep drug concentrations in 
the posterior segment of the eyeball, preventing the use of IVT injections or reduc-
ing their frequency. The advantage of using nanocarriers is their ability to increase 
the biopharmaceutical properties of the incorporated drug: solubility, stability, 
permeability, and retention at the site of application [17].
Nanocarriers are made of nanoparticles (NPs) (1–1000 nm), and they exemplify 
one of the multiple strategies of nanomedicine, which is interpreted as the application 
of NPs for medical purposes [18]. The most commonly used materials for NPs include 
lipids (liposomes), proteins (albumin NPs), cyclic oligosaccharides (cyclodextrins), 
synthetic polymers (polymeric micelles, dendrimers, hydrogel), and even inorganic 
compounds (cerium oxide NPs) [19]. Liposomes have been of much interest as carri-
ers for advanced drug delivery in medicine and, especially, in ophthalmology for their 
potential to avoid the sophisticated ocular barriers, even when they are topically applied. 
In fact, liposomes and cyclodextrins are the only topically administered nanoparticles 
that have successfully proven to release corticosteroids in clinical assays [20, 21].
In the following sections, we will review the ocular barriers and routes for ocular 
drug delivery and discuss the different nanocarriers topically used in preclinical 
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studies that have proven to elude the anatomic and physiologic conditions that 
prevent drugs from reaching the tissues in the posterior segment of the eyeball, 
emphasizing the leading role of liposomes.
2. Barriers for ocular drug delivery
The different barriers that hinder intraocular drug delivery may be classified 
into three categories (Table 1).
2.1 Static barriers
The static barriers in the eye are physical barriers that prevent the diffusion of 
drug molecules into the posterior segment of the eye and the retina. The cornea is 
a mechanical barrier that comprises the anterior sixth of the eye. This transparent, 
ellipsoid barrier has different layers that play an important role in drug permeation: 
each layer offers a different polarity and a potential rate-limiting structure for drug 
permeation. The corneal epithelium is lipoidal in nature, and it contains 90% of 
cells in the cornea. These cells are joined by desmosomes and surrounded by ribbon-
like tight junctional complexes. The presence of the zonula occludens delays paracel-
lular drug permeation from the tear film into intracellular spaces of the epithelium, 
as well as into the inner layers of the cornea [22]. The epithelium has a significant 
resistance against the permeation of topical hydrophilic drugs. The highly hydrated 
stroma that comprises 90% of the corneal layer is made up by an extracellular 
matrix and a lamellar arrangement of collagen fibrils, and it is an important barrier 
against the permeation of lipophilic drug molecules. The hexagonal-shaped cells, or 
endothelium, represent the innermost layer of the cornea, and they have a selective 
Table 1. 
Types of barriers for ocular drug delivery.
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carrier-mediated transport and a secretory function. New drug delivery systems 
should have an amphipathic nature in order to permeate through the cornea [23].
The sclera forms the firm, fibrous, outermost layer of the eye. It keeps the shape 
of the eye and provides an attachment for the insertion of the extraocular muscles. 
It is about 1 mm thick at the site where the optic nerve pierces it. The sclera is made 
of collagen and elastin chains that create a fiber matrix, where the pore diameter 
and intracellular spaces may determine the flow of drugs. Furthermore, the lateral 
orientation of fibers, the differences in the collagen architecture of the posterior sclera, 
and the differences in myopic eyes may affect drug transport with a lower or higher 
permeability depending on these changes. The permeability of the sclera for a num-
ber of molecules, such as dextrans, polyethylene glycol, anti-angiogenic molecules, 
antibiotics, oligonucleotides, and lipophilic compounds, has been measured [24–30]. 
There are different factors that may affect the scleral permeability of these molecules 
[2, 31–33]. Scleral permeability has a strong dependence on molecular weight, with 
smaller molecules having a better permeability. Similarly, since globular proteins are 
more permeable than linear dextrans of the same molecular weight, molecular radius is 
an important predictor of scleral permeability [32]. Finally, any surgical, pathological, 
or traumatic change in the anatomy of the sclera may lead to permeability changes [34].
Different studies on Bruch’s membrane—the choroid and the retinal pigment 
epithelium (RPE)—show that permeability increases when lipophilicity does 
the same. Molecules that are passively transported across the RPE show similar 
permeability values in both outward (retina-choroid) and inward (choroid-retina) 
directions, while molecules that are actively transported show differences in perme-
ability between the two of them [22]. The presence of RPE melanin may alter ocular 
drug disposition. Melanin binds to free radicals and drugs through electrostatic and 
van der Waals forces or through simple charge-transfer interactions with this pig-
ment, which may alter the availability of the free drug at the targeted site [35]. All 
basic and lipophilic drugs bind to melanin; thereby, melanin binding may signifi-
cantly lower pharmacological activity [36]. As a result of the presence of melanin, 
the binding of lipophilic compounds to the choroid-Bruch’s membrane is higher; 
consequently, there is greater resistance to solute permeation across the choroid-
Bruch’s membrane than across the sclera, which is devoid of melanin [37–39].
Aging does not alter the permeability or ultrastructure of the sclera, but the 
permeability of Bruch’s membrane and the choroid has shown to be significantly 
affected by age [2, 34]. Bruch’s membrane may be a major resistance barrier against 
the movement of small solutes due to an increase in its thickness with aging (from 
2 μm in the first decade of life to 4.7 μm in the tenth decade). Moreover, the accu-
mulation of lipid-rich membranous debris and basal laminar deposits may have an 
important role in drug delivery [39].
2.2 Dynamic barriers
Dynamic barriers include the clearance through lymphatic and blood vessels, 
bulk fluid flow, and the active transport mechanisms of RPE transporter proteins. 
Precorneal barriers are highly effective and include solution drainage, blinking, tear 
film, tear turnover, and induced lacrimation.
Blinking is a normal reflex that protects the eye from dryness, bright light, and 
fingers or other objects coming toward it. Blinking also regulates tears, which nourish 
and cleanse the surface of the eye. The blinking rate in newborns is only two times 
per minute. This increases to 14–17 times per minute in adolescence and remains at 
this rate throughout the rest of the lifetime. Blinking may also increase in response to 
pain, bright light, changes in temperature and humidity, and conversations.
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The tear film offers resistance, thanks to its high turnover rate. Mucin plays a 
protective role in tear film by forming a hydrophilic layer that moves over to the 
glycocalyx of the ocular surface and clears debris and pathogens [29, 40]. Human 
tear volume is estimated to be 7–10 μl, and the cul-de-sac can transiently contain 
around 30 μl of the administered eye drop. However, tear film displays a rapid 
restoration period of 2–3 min, and most of the topically administered solutions are 
washed away within just 15–30 s after instillation. Considering all of the precorneal 
factors, contact time with the absorptive membranes is lower, which is considered to 
be the primary reason for less than 5% of the applied dose reaching the intraocular 
tissues [41]. Precorneal fluid drainage is one of the main reasons for low ocular drug 
absorption [42–45].
After instillation, a big portion of an instilled volume (approximately from 
80 to 90%) is drained into the nasolacrimal duct. Nasolacrimal drainage helps 
maintain the volume of precorneal fluid at about 7–10 μl at all times [46]. A natural 
protective physiological mechanism causes the loss of any excess fluid present: it 
is drained out through the nasolacrimal duct. Similarly, other factors such as the 
instilled volume, viscosity, pH, tonicity, and drug type may also alter the regular 
ocular physiological process. The higher the instilled volume, the higher the rate 
of solution drainage; increasing the drug’s viscosity may extend contact time. 
Excessive tear production is associated with the instillation of acidic or alkaline 
solutions; hence the ideal ophthalmic formulation for topical delivery should be 
isotonic with tear secretions.
The conjunctiva is another effective barrier against ocular drug delivery. It is 
well vascularized, and drug molecules present in the conjunctiva and episcleral tis-
sues are cleared through blood and/or lymphatic vessels [47, 48]. Subconjunctively 
injected tracers have been detected in the cervical lymph nodes within 6 min [49, 
50]. Furthermore, molecular size and molecular radius may affect the rate of clear-
ance [2]. Future drug delivery systems will have to consider conjunctival/episcleral 
clearance mechanisms, given that they play a significant role in reducing intraocular 
drug penetration.
The choroid is a dark brown, highly vascularized layer located between the 
sclera and the retina. It extends from the ora serrata to the aperture of the optic 
nerve in the sclera. Drug molecules that are topically, systemically, and orally 
administered may be eliminated by the uptake of the rapid blood flow of the 
choroid. Drugs can be carried away by bulk fluid flows in ocular tissues and are 
ultimately mostly cleared through choroidal vasculature or conjunctival vascular 
and/or lymphatic vessels. Uveoscleral drainage has been reported within a range of 
4–60% [51], and it generates an outward bulk flow fluid from the suprachoroidal 
space. Many drugs may be carried away by the convective current of aqueous 
humor and cleared by the conjunctival vascular and/or lymphatic vessels. The 
effect of aging on uveoscleral outflow must also be considered by future drug 
delivery systems.
The osmotic pressure of the choroid in rabbits is 12–14 mmHg, and the vitreous 
humor has an osmotic pressure of approximately 0–1 mmHg [52]. This difference 
in osmotic pressure between the choroid and the vitreous generates a fluid flow 
toward the choroid. The hydrostatic pressure difference between the suprachoroid 
and the episcleral tissue also contributes to the outward bulk fluid flow [53]. There 
is a hydrostatic pressure difference of about 12 mmHg between the suprachoroid 
and the episcleral tissue, which works as a driving force for the outward bulk fluid 
flow. Drug efflux pumps, such as P-glycoproteins (P-gp) and multidrug resistance-
associated proteins (MRPs), have been reported in RPE with an efflux effect 
directed toward the choroid [54, 55]. Finally, organic ion transporters may have an 
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important role as active transport for drugs depending on extracellular pH, tem-
perature, and drug concentration [56].
2.3 Metabolic barriers
Transporters are membrane-bound proteins that play an important role in the 
active transport of nutrients or xenobiotics. These transporters play a significant 
role in humans in the processes of drug absorption, distribution, metabolism, and 
elimination. The presence of both efflux and influx transporters has been reported 
in various ocular tissues. The presence of efflux pumps in various ocular tissues has 
shown to regulate the intracellular drug concentration needed to achieve therapeu-
tic activity. Drug-metabolizing enzymes are present in many ocular tissues such as 
the ciliary body and RPE [57, 58]. As a defense mechanism, the eye possesses several 
sophisticated metabolizing enzyme systems that degrade drug molecules, including 
those of the cytochrome P-450 (CYP) family, which are the most important drug-
metabolizing enzymes. CYP3A isozyme, for example, metabolizes over 50% of 
commercial drugs [59].
3. Routes for drug delivery into the posterior segment of the eye
Designing a drug delivery system to target a specific tissue inside the eye is a 
challenge due to the different ocular barriers. Different modes of administration 
for drugs are available for ophthalmologists, but many of them fail to reach a 
therapeutic dose of the drug to elicit clinical effects. The different routes of ocular 
drug administration (Figure 1) include topical, oral/systemic, subconjunctival, 
subtenon, retrobulbar, intracameral, and intravitreal injections.
3.1 Topical administration
Topical administration is the most common method for drug administration in 
ophthalmology, mostly in the form of eye drops due to the ease of administration 
and the low cost. Topical application is useful in the treatment of disorders affecting 
the anterior segment of the eye [60]. The site of contact is the cornea, the conjunc-
tiva, and the sclera. A normal eyedropper delivers from 25 to 56 μL of topical for-
mulation with an average volume of 39 μL. However, an eye can transiently hold up 
to 30 μL, and the rest is lost either through nasolacrimal drainage or reflex blinking 
(5–7 blinks/min), significantly decreasing the overall drug available for therapeutic 
action. Furthermore, after a drop is administered to the eye, a major fraction of 
the drug is lost through lacrimation, tear dilution, nasolacrimal drainage, and tear 
turnover following topical administration. Such precorneal losses result in very low 
ocular bioavailability. Typically, less than 5% of the total administered dose reaches 
the aqueous humor [22, 61]. Therefore, in order to maintain minimum inhibitory 
concentrations, the agents need to be frequently dosed, resulting in poor patient 
compliance or potential adverse events. Physical barriers such as the cornea and 
the sclera and dynamic barriers such as reflex blinking, tear turnover, nasolacrimal 
drainage, conjunctival clearance, episcleral clearance, choroidal clearance, and 
clearance through bulk fluid flow and uveoscleral outflow are some of the many 
sophisticated barriers that cause poor drug molecule concentrations in the target 
organ (retina). For these reasons, topical administration is regarded as a poor 
option for the treatment of posterior diseases such as macular edema, age-related 
macular degeneration, and diabetic retinopathy.
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3.2 Oral/systemic administration
The oral and systemic administration of drugs is the most common drug deliv-
ery form in medicine (but this is not the case for eyes). Following oral/systemic 
administration, the blood-aqueous and blood-retinal barriers are major problems 
for drug delivery. The ciliary epithelium produces aqueous humor, which acts as an 
ultrafilter and restricts the entry of macromolecules such as antibiotics and plasma 
proteins [42]. Drug delivery to the posterior pole and the retina is very difficult due 
to the fact that blood-retinal barriers prevent the diffusion of drugs into the pos-
terior pole of the eye. BRBs are composed of retinal capillary endothelial cells and 
RPE, which are known as the inner and outer blood-retinal barriers, respectively. 
RPE is a monolayer of highly specialized cells, and it aids in biochemical functions 
by selectively transporting molecules between photoreceptors and choriocapil-
laris [38]. However, the tight junctions of RPE efficiently restrict intercellular 
permeation.
Drugs can easily enter the choroid, thanks to its high vasculature compared to 
that of retinal capillaries. The choriocapillaris are fenestrated, resulting in rapid 
equilibration of drug molecules in the bloodstream with the extravascular space of 
the choroid. However, RPE restricts further entry of drugs from the choroid to the 
retina. Because the blood-retinal barrier, which is selectively permeable to more 
lipophilic molecules, mainly governs the entry of drug molecules into the posterior 
segment of the eye, this results in the need for frequent administration of high 
amounts of drugs, which leads to systemic side effects [62].
Figure 1. 
Barriers for ocular drug delivery and different routes of drug administration to the eye. (1) Topical;  
(2) subconjunctival/subtenon; (3) intravitreal; (4) peribulbar; and (5) retrobulbar.
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Although topical and systemic routes are convenient, the lack of adequate 
bioavailability and the failure to deliver therapeutic amounts of drugs into the 
retina prompted vision scientists to search for alternative routes of administra-
tion. Hence, specific oral or intravenous targeting systems are needed to transport 
molecules through the choroid and into deeper layers of the retina [43]. An example 
of a systemic drug for the treatment of retinal diseases is Visudyne, which is used in 
photodynamic therapy for the treatment of wet age-related macular degeneration 
(AMD) and central serous chorioretinopathy (CSC). However, owing to toxicity 
and delivery concerns, intravenous administration is not very common in treating 
ocular diseases.
3.3 Periocular administration
Although not very patient compliant, these routes are partly used to overcome 
the inefficiency of topical and systemic dosing in order to deliver therapeutic 
drug concentrations to the posterior segment of the eye globe. Moreover, systemic 
administration may lead to side effects, making it a less desirable delivery route 
for geriatric patients. Periocular routes include subconjunctival, subtenon, retro-
bulbar, and peribulbar administrations, and they are comparatively less invasive 
than intravitreal routes. Drugs administered by periocular injections can reach 
the posterior segment through three different pathways: the transscleral pathway, 
systemic circulation through the choroid, and the anterior pathway through the 
tear film, cornea, aqueous humor, and vitreous humor [63]. The administration of 
a drug via subtenon injection resulted in the highest and more sustained vitreous 
concentration of drug molecules compared to other periocular injections [64]. 
However, anterior segment complications have been described in some patients 
following periocular injections. The complications include ocular hypertension, 
cataract, hyphema, strabismus, and corneal decompensation [65]. Additionally, the 
concentration of many drugs, such as that of anti-angiogenic drugs, is better if an 
intravitreal injection is used as a delivery pathway.
3.4 Intravitreal injection
Nowadays, intravitreal injection is the preferred route for ocular delivery for the 
treatment of diseases of the retina. It offers important advantages over periocular 
injections as drug molecules are directly inserted into the vitreous chamber. This 
method involves the injection of a drug solution directly into the vitreous, via the 
pars plana, using a 30-Ga needle. Unlike other routes, intravitreal injection offers 
higher drug concentrations in the vitreous and the retina. The advantage of IVT 
injection is the circumvention of the blood-retinal barrier, which keeps most drugs 
out of the eye in the case of oral and systemic administrations [43]. Therefore, IVT 
administration is able to maximize the intraocular level of drugs in the vitreous and 
the retina while avoiding toxicities associated with systemic treatment [66–69]. The 
benefits of intravitreal therapies in retinal diseases have been well documented, and 
the current standard of care is the injection of a bolus of anti-VEGF into the vitreous 
cavity on a frequent basis. Such a large bolus of a drug has been associated with some 
side effects [70]. In addition, this administration procedure creates a typical curve 
with a large peak of drug concentrations and a rapid decay. Literature supports the 
fact that the half-life of anti-VEGFs, such as ranibizumab, is indeed very short (half-
life = 2.6–4.0 days) [71], making it necessary to use a higher initial dose in order to 
exceed therapeutic levels so as to allow a longer 28-day treatment interval. Moreover, 
mathematical modeling demonstrates that the binding activity of 0.5 mg of ranibi-
zumab is fivefold higher if given every 14 days instead of every 28 days [72].
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Intravitreal injection can avoid ocular barriers for direct drug placement in the 
vitreous cavity, but drug distribution in the vitreous is not uniform. Small mol-
ecules can rapidly be distributed throughout the vitreous, whereas the diffusion 
of larger molecules is restricted. This distribution also depends on the presence of 
physiopathological conditions of the vitreous (vitrectomized patients present poor 
concentrations after 3 days) and the molecular weight of the administered drug 
[69]. In order to reach and maintain effective therapeutic concentrations, repeated 
injections are necessary. The frequent administration of drugs via this route can 
lead to endophthalmitis, damage to the lens, retinal detachment, and hemorrhage. 
Moreover, high acute intraocular drug concentrations may induce severe local toxic-
ity and increase intraocular pressure. Additionally, it may be a burden for physi-
cians, the health system, and patients with poor compliance in many cases [15]. 
Furthermore, IVT injections require highly specialized human resources and special 
infrastructure to apply them, and it is a costly option in developing countries [16].
Due to these limitations, new drug delivery systems are needed in order to 
find a safer and more effective ocular drug delivery method for the treatment of 
retinal diseases such as those from intraocular implants. Various drug delivery 
systems have been proposed using a group of biodegradable and nonbiodegradable 
platforms to passively deliver anti-angiogenic drugs [73–81]. However, one of the 
limitations of these drug delivery platforms is that, once implanted, they elute an 
unchangeable dosage of the drug and can only be stopped by explanting the device. 
In this context, they also share many of the problems of IVT injections.
4.  Topical nanocarriers for drug delivery into the posterior segment of 
the eyeball
To date, different nanocarriers have proven to be capable technologies to cir-
cumvent most of the ocular barriers and effectively deliver drugs to the posterior 
segment of the eye. Their favorable physicochemical properties, such as the small 
size and adjustable surface, render them advantageous in targeting drugs to the 
retina. Although different administration routes have been analyzed, we consider 
that the topical route is the one of greatest interest because of its favorable charac-
teristics such as its ease for the patient, a potentially better compliance, and lower 
incidence of serious complications than injected methods. The main topically 
proven nanocarriers are polymeric NPs, lipid nanoparticles, micelles, dendrimers, 
and liposomes.
4.1 Polymeric nanoparticles
Polymeric nanoparticles (PNPs) are colloidal particles (10–1000 nm) where 
the drug is uniformly distributed throughout the particle matrix (nanospheres) 
or encapsulated inside a polymer shell (nanocapsules) [82]. Synthetic and natural 
biocompatible polymers can be used to develop PNPs. The polymers used to gener-
ate PNPs for ocular applications have been made from poly(alkyl cyanoacrylates) 
[83, 84], polycaprolactone, chitosan (CS), hyaluronic acid (HA), Eudragit (RS100 
and RL100), Carbopol, gelatin, poly(butyl cyanoacrylate), polylactic acid (PLA), 
and poly(lactic-co-glycolic acid) (PLGA) [57, 85].
In regard to topical PNPs for posterior segment drug delivery, we would like to 
highlight the study performed by Tahara K et al., where submicron-sized poly(D,L-
lactide-co-glycolide) (PLGA) nanoparticles were used to improve the efficiency 
of drug delivery to the retina through topically administered drugs. Chitosan and 
glycol chitosan (GCS), which are mucoadhesive polymers, and polysorbate 80 
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(P80) were used as surface modifiers of PGLA nanoparticles since this substance 
increases the interaction of NPs with cells. Coumarin-6 was used as a model drug 
and a fluorescent marker. The in vivo fluorescence image analysis showed detect-
able fluorescence intensity of coumarin-6 in the retina of mice after its topical 
administration [86]. The author proposed that the delivery of coumarin-6 into the 
posterior segment was associated with ocular surface modifications induced by CS, 
GCS, or P80. However, they did not verify this hypothesis.
Another interesting work concerning topically administered PNPs for retinal 
drug delivery was the study performed by Binstock et al., where the penetration 
of charged fluorescent nanoparticles into rabbit eyes using hydrogel iontophoresis 
was evaluated. Polyacrylic hydrogels were loaded with charged nanoparticles. NP 
suspensions (20–45 nm) were administered using cathodal and anodal iontophore-
sis and applying a current intensity of 1.5 mA for 5 min at the central cornea and the 
sclera (pars plana). The mean fluorescence intensity in outer ocular tissues (cornea, 
conjunctiva, and sclera) was 2–3 times higher for positively charged NPs with anodal 
iontophoresis. In deeper ocular tissues (retina, choroid, ciliary body, and iris), the 
mean fluorescence intensity was 5–15 times higher for the negatively charged NPs 
with cathodal iontophoresis. The positively charged particles demonstrated better 
penetration into inner ocular tissues than negatively charged particles [87]. This 
work showed that hydrogel iontophoresis combined with charged nanoparticles 
could be a potential technique for effective retinal drug delivery, but the investiga-
tion will have to be broadened and the potential adverse events explored.
4.2 Lipid nanoparticles
Three different types of lipid nanoparticles (LNPs) have been used for ophthal-
mic formulations: solid lipid nanoparticles (SLNPs), nanostructured lipid carriers 
(NLCs), and hybrid lipid nanoparticles. SLNPs are aqueous colloidal dispersions com-
posed of solid lipids as a matrix material with the capacity to encapsulate hydrophilic 
and lipophilic drugs. SLNPs are provided with multiple advantages such as physical 
stability, protection of the encapsulated drug, controlled release, biocompatibility, 
feasible production, and the possibility of being sterilized by autoclaving [88–91]. On 
the other hand, SLNs have limited drug loading and expulsion for both hydrophilic 
and lipophilic drugs. Loaded drugs are usually located between fatty acid chains, in 
lipid layers, or in crystal imperfections [92]. NLCs consist of a mixture of solid and 
liquid lipids, and they exhibit a higher drug-loading capacity and longer stability than 
SLNPs [93]. Finally, hybrid lipid nanoparticles modified by multifunctional polymers 
[94] combine the merits of polymeric nanoparticles and lipid-based systems, which 
improve the pharmacokinetics and biodistribution of the loaded drug [95].
Experimentally, LNPs have been used for the delivery of substances to the 
posterior segment of the eye via corneal and non-corneal pathways. Araujo et al. [96] 
developed a nanometric (∼200 nm), unimodal, and negatively charged NLC loaded 
with the fluorescent lipid, Nile red (NR-NLC) marker and a drug, triamcinolone 
acetonide (TA). The method used for the construction of the NLC was high-pressure 
homogenization. After NR-NLC eyedrop instillation in mice, lipophilic actives were 
released into the posterior segment of the eye. Retinal fluorescence of Nile red gradu-
ally increased over time, peaking 40 min after administration and almost disappear-
ing at 160 min. The authors suggested that the fluorescence component of NR-NLC 
reached the retina through the BRB via non-corneal routes (sclera and conjunctiva).
In the work of Balguri et al., SLNPs and NLCs loaded with indomethacin (IN) 
were prepared through a hot homogenization method. Additionally, CS was used 
to modify the surface of SLNPs in order to increase penetration. After the topical 
application of formulations in rabbits, the concentration of IN was evaluated in 
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ocular tissues by using high-performance liquid chromatography (HPLC)-UV 
method. In vivo bioavailability studies demonstrated that the IN of the formulations 
(IN-SLNPs, IN-NLC, and IN-CS-NLC) reached the posterior ocular tissues 2 h post-
topical application. Moreover, the IN-NLC showed higher drug-loading capability, 
higher entrapment efficiency, less drug expulsion, and, especially, the highest 
distribution concentrations of IN in deeper ocular tissues (vitreous humor, choroid-
retina, and sclera). In vitro corneal penetration studies showed that CS increased 
corneal penetration by twofold (IN-CS-NLC compound), possibly thanks to the 
enhanced interaction with the mucus of the eye, the increased cellular uptake, and 
even its internalization. On the basis of their results, the authors proposed that the 
main transport routes of IN-NLC to successfully deliver IN to the posterior segment 
are the corneal pathway and the conjunctival-scleral pathway [97].
Finally, SLNPs comprising Compritol® 888 ATO and a polyethylene glycol 
(PEG) core, into which KTZ is dissolved, were topically used in rabbits. These 
SLNPs were generated by using a hot high-pressure homogenization method. 
Ocular pharmacokinetic studies indicated 2.5-fold and 1.6-fold increases in the 
aqueous humor and the vitreous humor via the topical administration compared to 
KTZ suspensions, respectively. Additionally, SLNPs were safe for the ocular sur-
faces of the study rabbits, and cell viability assays showed nontoxicity [98].
4.3 Polymeric micelles
Micelles (10–100 nm) comprise amphiphilic block copolymers above the 
critical micellar concentration with a hydrophobic core and a hydrophilic shell 
[99]. The preparation process of colloidal dispersions consists of the exposition of 
self-assembly oriented amphiphilic molecules in order to form core-shell monomer 
nanomicelles in a special solvent. These nanodispersions solubilize hydrophobic 
drugs by entrapping them within a mixed micellar hydrophobic core, resulting 
in clear aqueous formulations [100]. Micelles prevent or minimize drug degrada-
tion, improve drug permeation, increase the solubility and stability of drugs, and 
improve ocular bioavailability [101, 102].
Lately, nanomicelles/mixed nanomicelles loaded with different drugs such 
as dexamethasone [103, 104], voclosporin [105], and rapamycin [106] have been 
designed to reach the posterior segment of the eye. Liaw et al. [107] also demonstrated 
that micelles could be effective for intraocular gene delivery. In this work, pDNA 
with the lacZ gene was coupled to poly(ethylene oxide)-poly(propylene oxide)-
poly(ethylene oxide) (PEO-PPO-PEO) nonionic copolymeric micelles. Following 
topical administration, gene expression was detected around the rabbit iris, sclera, 
and conjunctiva, and it was also seen in the intraocular tissues of nude mice after topi-
cal application for 48 h. In another study, Cholkar et al. [108] optimized an aqueous 
micellar solution of isopropyl ester carrying the resolvin (RX-10045) prodrug. Ocular 
tissue distribution studies demonstrated significant drug concentrations in anterior 
ocular tissues. Moreover, RX-10008 (the active metabolite of RX-10045) was detected 
in the retina/choroid upon topical drop instillation in rabbits. Micelles appeared to 
follow the conjunctival-scleral pathway to reach the retina, and no evidence of ocular 
damage after multiple dosing of this micellar solution was observed [108].
4.4 Dendrimers
Dendrimers are highly branched treelike structures with a core and many 
side chain [109] moieties. The size of dendrimer nanoparticles is usually under 
100 nm, and peripheral functional groups (neutral, negative, or positive) may 
suffer secondary surface modifications in order to improve their characteristics for 
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ophthalmic use [110]. Due to their enhanced aqueous solubility, a large variety of 
surface groups, and their nontoxic nature, polyamidoamine (PAMAM) dendrimers 
have been investigated the most in regard to ocular drug delivery [111, 112].
Yavuz et al. [113] generated various anionic dexamethasone (DEX)-PAMAM 
complexes and evaluated the delivery of DEX to the posterior segment following 
topical administration in rats. The ocular tissue distribution study in rabbit eyes 
showed that anionic DEX-PANAM dendrimers reach the highest concentration of 
DEX in the vitreous body, the retina-choroid, and the sclera compared to topical 
DEX suspension. In addition, in vitro studies demonstrated that dendrimers with 
peripheral carboxyl or hydroxyl functional groups rarely showed cytotoxicity. 
Transport study results showed that dendrimer complexation increases DEX trans-
port across both corneal and scleral tissues. Additionally, dendrimers have proven 
their efficiency to release genetic material when topically administered [114].
4.5 Cyclodextrin nanoparticles
Cyclodextrins (CDs) are a family of natural cyclic oligosaccharides which are 
usually composed of no more than 20 a-D-glucopyranoside units via the covalent 
conjugation of α-1,4-glycosidic linkages. CDs are cyclic structures whose hydrophilic 
outer surface is enclosed by the lipophilic internal cavity of low polarity. The fea-
tures of their special structure predetermined their ease to form inclusion complexes 
for poorly water-soluble chemicals through non-covalent conjugations (electrostatic 
interactions, van der Waals contributions, hydrogen bonding, and charge-transfer 
interaction) [115]. CDs are not toxic for human beings [116], and they can improve 
the aqueous solubility, stability, activity, and dispersion of ophthalmic drugs [117].
Different types of oligomeric CD molecules are currently being used to produce 
cyclodextrin-based eye drops. These molecules are the β-CD [7], the γ-CD [8], its 
CD derivatives (hydroxypropyl-beta-cyclodextrin (HP-β-CD)), and the randomly 
methylated beta-cyclodextrin (RM-β-CD) [118]. Econazole nitrate (EC) and CD/
HP-β-CD were complexed to form different EC-CD inclusion complexes through 
coprecipitation in order to improve ocular bioavailability [119].
In the study of Loftsson et al. [120], inclusion complexes of dexamethasone and 
γ-CD were topically administered to rabbits. After 2 h of application, DEX reached 
its highest concentration in the vitreous and the retina. The same group performed 
a clinical trial to prove the efficiency of topical 1.5% dexamethasone γ-cyclodextrin 
nanoparticle eye drops (DexNP) compared to posteriorly the subtenon injection 
of triamcinolone acetonide in diabetic macular edema (DME) patients. Topical 
DexNP significantly improved visual acuity and decreased the macular thickness 
of patients with DME. The effect was similar to that of subtenon triamcinolone. 
However, a modest increase in intraocular pressure (IOP) was noted with DexNP, 
but IOP normalized after the discontinuation of the eye drops [21].
4.6 Liposomes
Liposomes were described for the first time by Alec Bangham in the 1960s at the 
Babraham Institute, University of Cambridge, and they consist of single or multiple 
concentric lipid bilayers encapsulating an aqueous compartment.
Liposomes as carriers for advanced drug delivery have been of much interest 
lately. They are biocompatible vesicles composed of a phospholipid bilayer with 
structural resemblance to the cell membrane that form small spheroids that are 
able to carry both hydrophilic and lipophilic drugs (Figure 2). Phospholipids 
combined with water immediately form a sphere as one end is water soluble, while 
the opposite end is water insoluble. Water-soluble medications added to water are 
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trapped inside the aggregation of hydrophobic ends and fat-soluble medications 
and incorporated into the phospholipid layer. Another significant characteristic of 
liposomes is their drug release rate, which depends on the liposomal composition, 
the nature of the drug, and the method of encapsulation.
Liposomes can be composed of naturally derived phospholipids with mixed lipid 
chains, like that of egg phosphatidylethanolamine, or pure components like dio-
leoylphosphatidylethanolamine (DOPE). The lipid bilayer can fuse with other bilay-
ers (e.g., the cell membrane), thus delivering the liposomal contents. By including 
liposomes in solutions with DNA or drugs (which would normally be unable to 
diffuse through the membrane), they can be delivered past the lipid bilayer. The use 
of liposomes for the transformation or transfection of DNA into a host cell is known 
as lipofection. Liposomes can be created by sonicating phospholipids in water. Low 
shear rates create multilamellar liposomes, which have many layers, like an onion. 
Continued high-shear sonication tends to form smaller unilamellar liposomes.
4.6.1 Types of liposomes
Depending upon their structure, there are two types of liposomes, unilamellar 
liposomes or unilamellar vesicles, which have a single phospholipid bilayer sphere 
enclosing an aqueous solution (Figure 3), or multilayer liposomes, which are 
multilamellar structures (Figure 4). In multilayer liposomes, several unilamellar 
vesicles will form one inside the other in diminished sizes, creating a multilamellar 
structure of concentric phospholipid spheres (like a Matryoshka doll) separated by 
layers of water. The structural components of liposomes could be:
• Phospholipids such as phosphatidylcholine, phosphatidylglycerol, phosphati-
dylinositol, etc. For stable liposomes, saturated fatty acids are used.
• Sphingolipids like sphingomyelin.
• Sterols, such as cholesterol, with the potential to decrease the fluidity or 
microviscosity of the bilayer. It can reduce the permeability of the membrane 
to water-soluble molecules and stabilize the membrane in the presence of 
biological fluids such as plasma.
Figure 2. 
Spherical formation of liposomes.
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• Synthetic phospholipids (saturated and unsaturated).
• Polymeric materials. Polymerized liposomes have significantly higher perme-
ability barriers to entrap aqueous drugs.
• Polymer-bearing lipids. Coating liposome surfaces with charged polymers 
results in repulsion interactions with macromolecules.
• Cationic lipids such as dioctadecyldimethylammonium bromide or chloride.
Figure 3. 
Single-layer liposome.
Figure 4. 
Multilayer liposome.
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4.6.2 Size of liposomes
Due to differences in preparation methods and lipid compositions, liposomes 
may be classified, according to their size, in small (<100 nm), medium (100–
250 nm), or large (>250 nm) [121, 122]. Some liposomes may be as small as <0.1 μm 
or as big as >1 mm in size.
4.6.3 Preparation method (incorporating drugs)
In addition to the ability to entrap drugs with different solubility character-
istics, it has been hypothesized that liposomes have different release kinetics. In 
general, multilamellar liposomes are more easily formed at larger hydrodynamic 
diameters, and, therefore, they have greater entrapped volumes than unilamellar 
liposomes. As a result of this, unilamellar liposomes with a hydrodynamic diameter 
of 130 nm exhibit a much faster release rate than multilamellar liposomes with 
two to three lamellar bilayers and a hydrodynamic diameter of 250 nm [123, 124]. 
The difference in the release rate is overall due to the number of phospholipid 
bilayers that it has to cross before being released [123, 124]. The ongoing interest 
of researchers in liposomal characteristics such as their stability, pharmacokinetic 
properties, and therapeutic efficacy has led to second-generation liposomes through 
the modulation of their lipid composition, size, and the charge of the vesicle. The 
addition of cholesterol to the lipid bilayer of liposomes reduces their permeability, 
increases their in vivo and in vitro stability, and can be used to anchor other mol-
ecules such as polyethylene glycol (PEG) or deoxyribonucleic acid (DNA) to the 
liposomes for their application in biosensing or as “stealth” drug carriers [124]. 
The use of phosphatidylcholine with saturated fatty acyl chains and materials that 
stretch transition temperatures beyond 37°C offered even greater stabilization [115, 
125]. Furthermore, hydrophilic carbohydrates or polymers, such as monosialogan-
glioside (GM1) and PEG, were included in the liposomal composition. GM1 can 
lead to the prolongation of the in vivo liposome viability time [126–129].
There are many different methods to prepare liposomes. According to Bozzuto 
and Molinari [130], the choice of the method depends on factors such as the 
physicochemical characteristics of liposomes and/or drug components; the toxicity 
and concentration of the loaded drug; the type of medium in which liposomes are 
dispersed; the additional process during the application/delivery of liposomes; the 
desired size for the application; the half-life desired for successful application; costs, 
reproducibility, and applicability regarding large-scale production for clinical pur-
pose; and good manufacturing practice-relevant issues. In addition, the target organ 
is a significant issue to be considered when planning the preparation of liposomes.
Every method for preparing liposomes involves four basic stages: drying down 
lipids from an organic solvent, dispersing the lipid in aqueous media, purifying the 
resultant liposome, and analyzing the final product. The most common methods for 
producing liposomes, according to Gabizon et al. [123, 128] and Akbarzadeh et al., 
[131] are the following.
5. Mechanical dispersion method
5.1 Handshaking and non-handshaking method
In order to produce liposomes, lipid molecules must be introduced into an aque-
ous environment. When a dry lipid layer film is hydrated, lamellae swell and grow 
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into myelin figures. Mechanical agitation provided by vortexing, shaking, swirling, 
or pipetting causes myelin figures to break and reseal the exposed hydrophobic 
edges, resulting in the formation of liposomes, which can be made by using the 
handshaking method.
5.2 French pressure cell method
It involves the extrusion of multilamellar vesicles (MLV) through a small orifice. 
The method involves the gentle handling of unstable materials. The resulting 
liposomes are larger than those generated by using the sonicated method. However, 
high temperatures are difficult to obtain and working volumes are small.
5.3 Freeze-thawed liposome method
The creation of unilamellar vesicles is a result of a fusion of UV throughout the 
processes of rapidly freezing and slowly thawing. The encapsulation rates go from 
20 to 30%.
5.4 The sonication method
The sonication method is the most used method for the preparation of lipo-
somes (unilamellar). Both techniques are probe sonication, in which the tip sonicator 
is directly immersed into the liposome. Dispersion is high and there is overheating, 
so the vessel is submerged in an ice bath. With this technique, up to 5% of the lipids 
can be de-esterified after 1 h. The bath sonicator is the second type of sonication 
method, and the dispersion of liposomes in a tube is placed into a bath sonicator. 
The regulation of the temperature is easier, and the lipid bilayer of liposomes can 
fuse with other bilayers, thus delivering the liposomal contents. By making lipo-
somes within drug solutions, they can be delivered past lipid bilayers.
6. Solvent dispersion method
6.1 Ether injection method
Ether injection method is also known as solvent vaporization. A solution of 
lipids dissolved in diethyl ether or an ether-methanol mixture is injected into 
an aqueous solution of the drug in order to be encapsulated at 55–65°C or under 
reduced pressures. The removal of ether under vacuum leads to the formation of 
liposomes.
6.2 Ethanol injection method
A lipid solution of ethanol is rapidly injected to a huge buffer excess. 
Multilamellar vesicles are at once formed. Unfortunately, the population is not 
homogeneous with this method.
6.3 Reverse-phase evaporation method
Reverse-phase evaporation method is based on the formation of inverted 
micelles. These inverted micelles are formed upon the sonication of a mixture of a 
buffered aqueous phase, which contains the water-soluble molecules to be encapsu-
lated into the liposomes, and an organic phase, in which the amphiphilic molecules 
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are solubilized. The slow removal of organic solvent leads to the transformation of 
these inverted micelles into a gel-like, viscous state. After the gel-state collapses, 
some of the inverted micelles disintegrate, but the excess of phospholipids in the 
environment contributes to the formation of a complete bilayer around the remain-
ing micelles, which results in the formation of liposomes.
7. Detergent removal method
7.1 Dialysis method
As the detergent is detached, the micelles increasingly become better-off in 
phospholipids, and, lastly, they combine to form UVs.
7.2 Detergent removal of mixed micelle method
The absorption method is attained by shaking mixed micelle solution with 
beaded organic polystyrene absorbers.
7.3 Gel permeation chromatography method
In this method, the detergent is depleted through size special chromatography.
7.4 Dilution method
The spontaneous transition from polydispersed micelles to vesicles occurs due 
to the dilution of the aqueous micellar solution of detergent and phospholipids with 
buffer.
7.5 Stealth liposomes and conventional liposomes
Liposomes become known by the mononuclear phagocytic system following 
contact with plasma proteins. This is solved through the use of synthetic phospho-
lipids, particle coated with amphipathic polyethylene glycol, coating liposomes 
with chitin derivatives, freeze drying, polymerization, and microencapsulation of 
gangliosides. A stealth liposome is a sphere-shaped vesicle with a membrane that is 
composed of a phospholipid bilayer used to deliver drugs or genetic material  
to a cell.
Drug loading can be achieved through passive (if the drug is encapsulated 
during liposome formation) or active methods (after liposome formation). 
Freeze-dried (lyophilization) liposomes are formed from preformed liposomes 
at tremendously low pressures. Very high encapsulation efficiencies, even for 
macromolecules, can be achieved using this method. During dehydration, the 
lipid bilayers and the drug to be encapsulated into the liposomes are brought into 
close contact. Upon reswelling, the chances for the encapsulation of the adhered 
molecules are much higher. Rehydration is a very important step and it should be 
very carefully done. The aqueous phase should be added in very small portions 
with a micropipette to the dried materials. After each addition, the tube should be 
thoroughly vortexed.
7.5.1 Transportation mechanisms
Liposomes can interact with cells through different mechanisms [129]:
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Endocytosis. Carried out by phagocytic cells of the reticuloendothelial system 
such as macrophages and neutrophils.
Adsorption to the cell surface either through nonspecific weak hydrophobic or 
electrostatic forces or specific interactions with cell surface components.
Fusion with the plasmatic cell membrane through the insertion of the lipid 
bilayer of the liposome into the plasma membrane with the simultaneous release of 
the liposomal content into the cytoplasm.
Transfer of liposomal lipids to cellular or subcellular membranes, or vice versa, 
without any association of liposomal contents.
7.5.2 Evaluation
Liposomal formulation and processing for a specific purpose are character-
ized for ensuring their predictable in vitro and in vivo performance [132]. 
Characterization parameters for the purpose of evaluation may be classified into 
three broad categories that include:
Physical characterization. It evaluates the size, shape, surface features, lamellar-
ity, phase behavior, and drug release profile.
Chemical characterization. It includes studies in order to establish the purity and 
potency of various lipophilic constituents.
Biological characterization. Biological characterization is helpful in establishing 
the safety and suitability of the formulation for therapeutic applications.
Some parameters are the vesicle’s shape and lamellarity, vesicle size and size 
distribution, encapsulation efficiency (expressed as percentage (%)), phase 
response, and transitional behavior and drug release. Zeta potential (ZP) refers 
to the potential difference between the electric double layer (EDL) (an adsorbed 
double layer developed on the surface of dispersed charged particles) of movable 
particles and the layer of dispersant around them at the slipping plane. A stabilized 
nanosuspension is a suspension that may be affected by several factors such as pH, 
ionic strength, and the concentration of particles. The phospholipid composition of 
liposomes is the main content that influences the overall surface charge of liposomes.
7.5.3 Applications of liposomes in medicine
Liposomes are versatile carriers for the delivery of numerous challenging mol-
ecules, and they have remarkable advantages compared to other colloidal systems. 
They have been investigated for a wide range of applications in pharmaceutical 
technology through topical, transdermal, nasal, and oral routes for efficient and 
effective drug delivery. Liposome formulations have potential advantages that other 
drug delivery systems do not have:
i. Suitable for the delivery of hydrophobic, amphipathic, and hydrophilic 
drugs.
ii. They protect the encapsulated drug from the external environment.
iii. Reduced toxicity and increased stability.
iv. Increased efficacy and therapeutic index of the drug.
v. The sustained-release system of systematically or locally administered 
liposomes.
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vi. Improved transfer of hydrophilic, charged molecules.
vii. Improved penetration into the tissues.
viii. Site avoidance mechanism.
ix. They offer site-specific targeting.
x. Nontoxic, flexible, biocompatible, and completely biodegradable.
xi. Size may vary in order to incorporate smaller or larger drug molecules.
xii. They can be administered through various routes.
xiii. The therapeutic activity of chemotherapeutic agents may be improved 
through liposomal encapsulation. This reduces deleterious effects similar to 
or lower than those required for maximum therapeutic activity.
xiv. They help reduce exposure of sensitive tissues to toxic drugs.
Some of the disadvantages of liposomes are:
i. Production cost is high.
ii. Leakage and fusion of encapsulated drug molecules with certain preparation 
methods.
iii. Short half-life.
iv. Less stability.
v. Low solubility.
vi. Phospholipids undergo oxidation and hydrolysis.
vii. Leakage and fusion.
viii. Allergic reactions to liposomal constituents may occur.
Liposomal formulations have several applications in cancer chemotherapy. 
Due to the nature and behavior of cancer tissues and the large difference between 
them and regular tissues, cancer tissues are considered an appropriate target for 
liposome drug delivery systems. For example, the tumor vasculature is character-
ized by a leaky vasculature and limited lymphatic drainage; consequently, drug 
molecules can easily be accumulated in intercellular spaces of a large variety of 
tumors. Numerous different liposome formulations of several anticancer agents 
were shown to be less toxic than free drugs [131, 133–135]. Examples of these drugs 
are doxorubicin and daunorubicin citrate for Kaposi sarcoma; doxorubicin for 
ovarian cancer and solid tumors; nystatin, vinorelbine, cisplatin and its analog 
docetaxel, tretinoin, siRNA, topotecan, irinotecan, paclitaxel, and camptothecin for 
solid tumors; cisplatin and its analog for colorectal neoplasms, Grb-2 in leukemia; 
Bcl-2 for lymphoma; BikDD for pancreatic cancer; and DOTAP (Chol-Fus I) for the 
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treatment of lung cancer [130]. Many other drugs are being researched in order to 
make them affordable for liposomal drug delivery systems.
In dermatology, liposomes have successfully been used in atopic dermatitis (tax-
ifolin glycoside) as antibacterial, antifungal (metronidazole nitrate, amphotericin 
B), and anti-leishmaniasis treatments (amphotericin B, meglumine antimoniate). 
Antioxidants such as natural flavonoids (catechin and naringenin) have been used 
to prevent the oxidation of cutaneous disorders and as photoprotective (quercetin), 
antipsoriatic, anti-inflammatory agents and anti-acne drugs [136].
In the same context, prostaglandin has been used in peripheral vascular disease, 
meglumine antimoniate for cutaneous leishmaniasis, fentanyl for pain relief, 
amikacin in cystic fibrosis, and prilocaine in dental anesthesia, all of them are more 
examples of liposomal drug products for medical use [136]. Furthermore, antihy-
pertensive drugs have been used for the management of cardiovascular disorders 
(propanol hydrochloride, valsartan, and nifedipine have been developed in liposo-
mal formulations) [136]. There are publications regarding local anesthetic drugs 
[137–139], drug delivery to the brain in anti-migraine and anti-Parkinson drugs 
[140–143], and the nasal delivery of liposomal formulations (salbutamol).
The application of liposomes in vaccine formulations and toxoids is one of the 
main achievements of modern medicine. Vaccination activates particular parts of 
the immune system in order for it to express specific immune responses followed 
by the induction of long-lasting immunological memories to defend against subse-
quent infectious attacks [144]. Most available immunizations are intramuscularly 
delivered, which is painful and requires an aseptic technique, as well as skilled and 
trained personnel for their administration. Thus, biological products (vaccines 
and toxoids) are suitable as a noninvasive approach compared to conventional 
methods, and they have numerous obvious advantages such as increased patient 
compliance, reduced systemic side effects, and constant plasma concentrations. 
Ding et al. reported on antigens such as vaccines and toxoids. Depending on the 
type of antigens, the dose to be delivered, immunization schedule, the presence of 
co-stimulatory factors, and liposomal composition, the immunization of antigens 
loaded in ELs elicits an effective immune response with serum IgG levels compa-
rable to those obtained after subcutaneous injections [145–148]. Transcutaneous 
immunization (TCI) is a novel technique, and it requires the simple introduction 
of antigens into the host tissue through topical application on the skin [148]. This 
offers ease of administration and the potential to elicit a robust immune response 
as compared to conventional painful (needle injections) methods prescribed in 
equivalent doses [145].
Image-guided delivery is another opportunity area for liposomal formulations. 
Imaging plays an integral part in modern precision and individualized medi-
cine. Wide applications of imaging such as monitoring drug delivery, accurate 
diagnosis of diseases, determining the response to therapy, and guiding mini-
mally invasive procedures are some of the applications of imaging in the clinic. 
However, traditional imaging modalities, such as computed tomography (CT), 
positron-emission tomography (PET), magnetic resonance imaging (MRI), and 
single-photon emission computed tomography (SPECT), all suffer from target 
specificity, which limits their clinical utility. Nanoparticles, with their versatility 
in surface functionalization, provide opportunities to enhance target specific-
ity and label NPs with various isotopes, which enables them to act as contrast 
agents. Recent developments in multimodality imaging to better diagnose diseases 
and monitor treatments have embarked on using liposomes as a diagnostic tool. 
Conjugating liposomes with different labeling probes enable the precise localiza-
tion of these liposomal formulations by using various modalities such as PET, 
SPECT, and MRI [149].
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Glucocorticoids (GC) are one of the most popular and versatile classes of drugs 
available to treat chronic inflammation and cancer, but side effects and resistance 
constrain their use. In order to overcome these hurdles, which are often related to the 
uniform tissue distribution of free GC and their short half-life in biological fluids, 
new delivery vehicles have been developed, including PEGylated liposomes, poly-
meric micelles, polymer-drug conjugates, inorganic scaffolds, and hybrid NPs. While 
each of these nanoformulations has individual drawbacks, they are often superior to 
free GC in many aspects, including therapeutic efficacy when tested in cell cultures 
or animal models. The characterization and pharmacokinetics of triamcinolone 
acetonide-loaded liposomal topical formulations for vitreoretinal drug delivery [150] 
have been published by Altamirano-Vallejo et al. They showed that a formulation 
with triamcinolone acetonide-loaded liposomes is feasible and that it has the poten-
tial to reach the vitreous cavity with a significant concentration of the drug.
Liposomal vesicles have potential advantages when compared to conventional 
drug delivery methods. Liposomes in different forms are still one of the most 
investigated drug delivery carrier systems for the ocular delivery of drugs in both 
preclinical studies and clinical trials. They seem to be an almost ideal drug-carrier 
system since their morphology is similar to that of cellular membranes and because 
of their ability to incorporate various substances. They are valued for their biologi-
cal and technological advantages as optimal delivery systems for biologically active 
substances, both in vitro and in vivo, and are considered to be the most successful 
drug-carrier system known to date [151].
7.5.4 Liposomes in ophthalmology
Several liposome formulations have been used in ophthalmology to target the 
anterior segment of the eye. The use of liposomal formulations to enhance the 
bioavailability of topical applied acyclovir and ganciclovir has been evaluated with 
promising results [152]. Antibacterial drugs, such as tetracycline, gentamycin, 
ciprofloxacin, norfloxacin, and chloramphenicol, have been prepared as liposo-
mal solutions with higher activity compared to that of standard solutions [153]. 
Antifungal agents such as amphotericin B and fluconazole have been under research 
[152], and liposomal formulations were highly effective in treating Candida kerati-
tis. Anti-inflammatory drugs and immunomodulatory agents are widely used in the 
treatment of ocular inflammatory and immunological diseases. In order to enhance 
ocular bioavailability and reduce the toxic effects following topical or intravitreal 
administration, liposomal forms of many of these drugs have been evaluated 
(diclofenac, cyclosporine, tacrolimus) with promising results and better concentra-
tions than standard formulations [152, 153]. Similarly, liposomal antiglaucoma 
agents’ formulations (pilocarpine, latanoprost, acetazolamide) were more effective 
in reducing intraocular pressure (IOP). In the same context, lubricants and antioxi-
dants have also other potential uses for liposomal formulations.
Liposomal drugs that have transitioned from preclinical research to clinical 
phase trials include latanoprost-loaded conventional liposomes developed for 
subconjunctival administration [154]. Phase I and II trials on the safety and effi-
cacy of latanoprost-loaded liposomes in the treatment of ocular hypertension and 
primary open-angle glaucoma have been completed (ClinicalTrials.gov identifier, 
NCT0198732357; ClinicalTrials.gov identifier, NCT02466399).
7.5.5 Topical liposomes for drug delivery into the posterior segment of the eyeball
Different efforts have been performed to deliver drugs into the posterior seg-
ment of the eye through the instillation of loaded liposomes (Table 2) [155–163]. 
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Drug Liposome 
description
Liposomal composition Synthesis method Main findings Clinical 
trials
Reference
Coumarin-6 Poly-L-lysine 
surface-modified 
liposomes
Poly-L-lysine, EPC, DCP, 
and CH
Hydration method Noncytotoxic in corneal and conjunctival cells No [155]
Coumarin-6 Submicron-sized 
liposomes (ssLips)
DSPC, EPC, DCP or SA, 
and CH
Hydration method Delivery efficiency of coumarin-6 to the retina was 
altered depending on particle size
No [157]
Coumarin-6 Submicron-sized 
liposomes (ssLips)
EPC or DSCP, DCP, and CH Hydration method The magnitude of fluorescence in the retina was 
closely related to both liposome rigidity and particle 
size. Images of the entire eye showed that ssLip 
was delivered via the non-corneal pathway after 
administration
No [162]
5(6)-Carboxyfluorescein Submicron-sized 
liposomes (ssLips)
DSPC and EPC Calcium acetate 
gradient method that 
implies hydration and 
is freeze-thawed
Luminescence intensity in the retina was higher 
when a ssLip formulation composed of DSPC was 
applied
No [161]
Diclofenac PVA 205 or PV-R 
surface-modified 
liposomes
PVA 205 or PV-R, DSPC, 
and CH
Calcium acetate 
gradient method that 
implies hydration and 
is freeze-thawed
The increase in particle size of the liposomal 
formulation was inhibited in the presence of PVA 
205 or PV-R. In vivo animal study revealed that the 
concentration of diclofenac in the retina-choroid 
was enhanced 1.8-fold through surface-modified 
liposome entrapment compared to that of the 
unaltered diclofenac solution
No [158]
Edaravone Submicron-sized 
liposomes (ssLips)
EPC and CH Calcium acetate 
gradient method that 
implies hydration and 
is freeze-thawed
Edaravone-loaded ssLips showed a stronger inhibition 
of in vitro light-induced ROS production and cell 
death than free edaravone. ssLips showed modest 
cytotoxicity
No [159]
Triamcinolone acetonide Triamcinolone 
acetonide-loaded 
liposomes 
formulations 
(TA-LF)
Polyethylene glycol (PEG-
12) glyceryl dimyristate
QuSomes®; 
self-forming, 
thermodynamically 
stable
TA-LF, topically administered, can deliver TA to the 
vitreous cavity and efficiently reach the retina with 
no adverse effects in rabbits. TA-LF was well tolerated 
and improved the best corrected visual acuity and the 
central foveal thickness in patients with refractory 
pseudophakic cystoid macular edema
Yes [150]
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Drug Liposome 
description
Liposomal composition Synthesis method Main findings Clinical 
trials
Reference
Triamcinolone acetonide Triamcinolone 
acetonide 
chitosan-coated 
liposomes 
(TA-CHL)
Chitosan, 
phosphatidylcholine, and CH
Calcium acetate 
gradient method that 
implies hydration and 
is freeze-thawed
TA-CHL penetrates into the posterior segment of the 
eye. Chitosan-coated liposomes were a more efficient 
ocular delivery system of triamcinolone acetonide to 
the posterior segment of the eye as eye drops than non-
coated liposomes
No [164]
Bevacizumab Annexin 
A5-surface-
modified 
liposomes
Phosphatidylserine, 
phosphatidylethanolamine, 
and anionic phospholipid-
binding protein annexin A5
Calcium acetate 
gradient method that 
implies hydration and 
is freeze-thawed
Annexin A5-surface-modified liposomes deliver 
physiologically significant concentrations of 
bevacizumab to the posterior segment of rat eyes 
(127 ng/g) and rabbit retinas (18 ng/g). Annexin 
A5-mediated endocytosis enhances the delivery of 
bevacizumab
No [156]
pDNA pDNA/PEI 
complex-loaded 
liposomes 
modified with 
transferrin
EPC and CH Detergent removal 
method
The modification of ligand (transferrin), which binds 
to a specific receptor in RPE cells to the liposomes, 
improves gene delivery efficacy to the posterior 
segment of the eye
No [160]
Plasmid DNA with 
β-galactosidase gene
TMAG liposome 
and DC-CH 
liposome
TMAG liposomes, TMAG 
and DOPE; DC-CH 
liposome, DC-cholesterol 
and DOPE
Hydration method Gene expression was found in retinal ganglion cell 
until 1 month after the topical application of liposomes
No [163]
CH, cholesterol; DC, dicetyl phosphate; DC-cholesterol, 3beta [N-(N′-N′-dimethylaminoethane)-carbamyl] cholesterol; DLPC, dilauroylphosphatidylcholine; DOPE, dioleoylphosphatidylethanolamine; 
DSPC, L-α-distearoyl phosphatidylcholine; EPC, egg phosphatidylcholine; PEI, polyethylenimine; PVA 205, polyvinyl alcohol; PVA-R, polyvinyl alcohol derivatives bearing a hydrophobic anchor (C16H33 S) 
at the terminal of the molecule; SA, stearyl amine; TMAG, N-(alpha-trimethyl ammoniacetyl)-didodecyl-D-glutamate.
Table 2. 
Reported liposomes for drug delivery to the posterior segment of the eyeball.
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For example, fluorescent probes used as drug models, such as coumarin-6 and 
5(6)-carboxyfluorescein, have efficiently been released into the posterior segment 
of the eyeball by liposomes [155, 157, 161, 162]. On the other hand, drugs like 
edaravone and diclofenac were successfully released into the vitreous and the retina 
by liposomes [158, 159].
Special mention is reserved for the study performed by Davis BM et al. This 
group demonstrated that the topical instillation of eye drops containing annexin 
A5 associated with liposomes loaded with bevacizumab is able to deliver physi-
ologically significant concentrations of this large therapeutic protein (monoclonal 
antibody against vascular endothelial growth factor A) into the posterior segment 
of the eye in animal models (rats and rabbits) [156]. Moreover, liposomes can 
release genetic material into the vitreous and the retina [160, 163].
Lastly, a topical triamcinolone acetonide-loaded liposomes formulation (TA-
LF) was used to successfully deliver TA into the vitreous and the retina of rabbits. 
Besides the authors report that TA-LF was well tolerated by the study animals 
and that no toxicity was observed in cell culture assays and no adverse events like 
corneal and conjunctival erosions were observed [150]. Recently, Jin Li et al. [164] 
validated in animal models (mice) that eye drops containing chitosan-coated 
liposomes carrying TA are an efficient method to deliver this drug into the pos-
terior segment of rabbit eyeballs, supporting the previous findings published by 
Altamirano-Vallejo et al. Even though Li et al. reached superior TA entrapment 
efficiency in their TA-loaded liposomes prepared through the calcium acetate gradi-
ent method, it seems that this characteristic does not compromise the therapeutic 
activity of TA-LF. TA-LF has been tested in clinical assays where its efficiency and 
safety profile have satisfactorily been demonstrated. In a recent report, TA-LF was 
efficient in the management of refractory pseudophakic cystoid macular edema 
[20], where the use of this formulation was associated with the improvement of 
best corrected visual acuity and central foveal thickness with no reports of adverse 
events. At this time, phase II trials are underway to demonstrate the efficacy of 
TA-LF for macular edema.
8. Conclusion
Although there has been great interest in the development of new topical ocular 
delivery systems, the topical administration of drugs is not as effective as intravit-
real delivery in treating retinal diseases. During topical delivery, drug molecules 
must cross several anatomic and physiologic barriers before reaching the posterior 
segment of the eye. Consequently, very low concentrations, with almost no clinical 
effect, are usually obtained. However, dramatic changes have been observed in the 
field of ocular drug delivery over the last decade, and nanomedicine is one of the 
most promising technologies for efficient drug delivery into intraocular tissues. 
Nanocarriers have a great potential to solve the challenge of releasing drugs into the 
posterior segment of the eyeball and reaching deeper intraocular tissues. Different 
nanocarriers, such as NPs, LPs, micelles, dendrimers, cyclodextrin nanoparticles, 
and liposomes, have been developed for the safe and effective drug delivery to the 
vitreous and the retina. Nevertheless, only a few of these particles have clinically 
been approved (liposomes and CDs among them).
Liposomes have lately been of great interest as carriers for advanced drug deliv-
ery in medicine and, especially, in ophthalmology due to their potential to avoid 
sophisticated ocular barriers when they are topically used. Liposomal drug delivery 
systems have a bright future in ophthalmology and, particularly, for the retina for 
several reasons. First, features such as the passive-targeting effect may substantially 
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enhance the amount of drug in target tissues. Second, liposomal technology 
allows the therapeutic index of already established drugs, with well-established 
therapeutic profiles, to be improved. This eliminates some of the considerable risks 
associated with the development of new pharmaceutical products. Third, many of 
the potential new pharmaceutical products arising from advances in biotechnology 
would come from macromolecules such as proteins, peptides, oligonucleotides, and 
plasmids, which could easily be carried by liposomes so as to access target tissues 
and cells. Additionally, liposomes possess features of optimal drug delivery systems 
to get to the ocular surface and intraocular tissues, for instance, sustained and con-
trolled drug delivery, ease to instill for the patient, good corneal-scleral penetration, 
and the fact that they reach appropriate concentrations of the drug in the target 
tissue, avoid side effects produced by conventional systems (like IVT injections), 
there is better patient compliance, and they are potentially affordable for patients. 
A proof of the clinical advantages of liposomes is represented by recent trials where 
TA-loaded liposomes have successfully been used to treat macular edema.
Considering that liposomes collect the main characteristics of an optimal drug 
delivery system and that these nanocarriers have proven their capacity not only 
to deliver drugs but also genetic materials to the posterior segment of the eye, we 
consider that liposomes are promising nanoparticles for the therapy of multiple 
intraocular illnesses.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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